How often should I receive the meningococcal conjugate (Men‑C) vaccine?

Meningococcal Conjugate Vaccine Frequency

For healthy adolescents, you should receive the meningococcal conjugate vaccine (MenACWY) at age 11-12 years with a single booster dose at age 16 years. 1

Standard Vaccination Schedule

Routine Adolescent Vaccination

• Initial dose: One dose at age 11-12 years
• Booster dose: One dose at age 16 years (if first dose given before 16th birthday) 1
• Late vaccination: If first dose given at age 13-15 years, give booster at age 16-18 years 2
• No booster needed: If first dose given at or after age 16 years 2

The rationale for this two-dose schedule is based on evidence showing vaccine effectiveness wanes over time. Research demonstrates that while initial effectiveness is 79% in the first year, it decreases to 61% by 3-8 years post-vaccination 3. The booster at age 16 provides protection during the period of highest risk in late adolescence and early adulthood.

Adults and Children Outside Routine Age

• Ages 2-10 years: Not routinely recommended unless at increased risk 1
• Ages ≥24 years: Not routinely recommended unless at increased risk 1

High-Risk Populations Requiring Different Schedules

Individuals with Persistent Increased Risk

If you have complement deficiencies, functional/anatomic asplenia, or HIV infection:

• Primary series: Two doses given 2 months apart (not just one dose) 2
• Booster frequency:
  • Ages <7 years: Booster at 3 years after primary vaccination, then every 5 years 1
  • Ages ≥7 years: Booster at 5 years after primary vaccination, then every 5 years 1

Young Children (9-23 months) at High Risk

• Primary series: Two doses given 3 months apart 4

Important Caveats

College students: If you're a college freshman living in residence halls, ensure you received at least one dose within 5 years before college entry, preferably on or after your 16th birthday 1. If your only dose was before age 16 and it's been more than 5 years, you need a booster before enrollment.

Continued risk: The booster interval of "at least 4 years" mentioned in FDA labeling 4 applies specifically to individuals at continued risk for meningococcal disease (travelers to endemic areas, microbiologists, outbreak situations), not routine adolescent vaccination.

Vaccine interchangeability: The different MenACWY products (MenACWY-D/Menactra, MenACWY-CRM/Menveo, MenACWY-TT/MenQuadfi) are considered interchangeable for routine vaccination 1, though some evidence suggests maintaining the same carrier protein may optimize responses 5.